Dr Susan Currie

Reader

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

Susan Currie obtained her PhD in Biochemistry (cellular signalling and molecular pharmacology) from the University of Glasgow in 1992 then spent two years at Lilly Research Laboratories, USA, where she studied the role of phospholipase A² in mast cell activation. She returned to the University of Glasgow in 1994 to join the then newly formed Clinical Research Initiative in heart disease and became a founder member of the school of cardiovascular studies in Glasgow. During this time she progressed from postdoctoral researcher to Principal Investigator examining the role of Calcium/calmodulin protein kinase ll (CaMKll) in cardiac hypertrophy and heart failure. She moved to the University of Strathclyde in 2005 as a Lecturer in Physiology & Pharmacology and established an independent cardiovascular signalling research group with principal interests in CaMKll modulation of cardiac calcium handling and cardiac inflammation. CaMKll as a therapeutic target in cardiac disease remains a key focus of research and characterising the actions of this enzyme is ongoing. More recent research interests include cardiotoxicity in the context of safety pharmacology as well as altered cardiovascular function in ageing.

Dr Currie is currently chair of the Scottish Cardiovascular Forum and full member of the Physiological Society and Biophysical Society, as well as being the Strathclyde University representative for the Physiological Society. She was made a Fellow of the Physiological Society in 2017 in recognition of her contribution to cardiovascular research and the discipline of Physiology. She currently teaches on a wide range of classes across both the MPharm and Biomedical Sciences programmes at the University of Strathclyde and coordinates classes on the MPharm programme. She was awarded Fellowship of the Higher Education Academy in 2008. She currently co-directs the collaborative MPharm programme between the University of Strathclyde and the International Medical University (IMU) in Kuala Lumpur, acting as MPharm representative on the internationalisation committee and is Deputy Director of the MPharm programme at the University of Strathclyde.

Publications

Characterising endothelial CaMKII oxidation in a cellular model of inflammation to investigate the therapeutic potential of a novel anti-oxidant stent coating
Longhorn Daniel, McCormick Christopher, Currie Susan
36th Annual Meeting of the International Society for Heart Research European Section International Society of Heart Research (2021)
Cobalt-induced cardiomyopathy - do circulating cobalt levels matter?
Jenkinson Mark R J, Meek Dominic R M, Tate Rothwelle, MacMillan Sandy, Grant M Helen, Currie Susan
Bone and Joint Research Vol 10, pp. 340–347 (2021)
https://doi.org/10.1302/2046-3758.106.BJR-2020-0414.R2
Assessing the anti-oxidant capacity and therapeutic potential of a novel coronary artery stent coating
Longhorn Daniel, Currie Susan, McCormick Christopher
Scottish Cardiovascular Forum 2021 (2021)
Sunitinib and imatinib display differential cardiotoxicity in adult rat cardiac fibroblasts that involves a role for calcium/calmodulin dependent protein kinase II
McMullen Calum J, Chalmers Susan, Wood Rachel, Cunningham Margaret R, Currie Susan
Frontiers in Cardiovascular Medicine Vol 7 (2021)
https://doi.org/10.3389/fcvm.2020.630480
Parallel development and characterisation of an anti-oxidant stent coating and an in vitro biological model for qualitative assessment
Longhorn Daniel, Currie Susan, McCormick Christopher
Heart Vol 106 (2020)
https://doi.org/10.1136/heartjnl-2020-SCF.5
Sunitinib mediates mitochondrial ROS production in adult rat cardiac fibroblasts via CaMKII oxidation
McMullen CJ, Chalmers S, Cunningham MR, Currie S
Heart Vol 106 (2020)
https://doi.org/10.1136/heartjnl-2020-SCF.8

More publications

Professional activities

Heart Research UK Scotland annual event
Speaker
7/6/2021
Novel off-target effects of doxorubicin on cardiovascular gap-junctional proteins
Contributor
5/2/2021
Scottish Cardiovascular Forum 2021
Organiser
2/2021
Assessment of the cardiac work-loop to identify drug-induced changes in contractility using rat papillary muscles (Coventry University)
Examiner
2021
Suppressor of cytokine signalling 3 (SOCS3) turnover and regulation of human saphenous vein smooth muscle cell signalling and function (University of Bradford)
Examiner
2021
Experimental Biology
Organiser
2021

More professional activities

Projects

Remodelling of E-C coupling in heart failure with preserved ejection fraction (HFpEF)
Currie, Susan (Co-investigator)
01-Jan-2021 - 30-Jan-2024
Cross-examining interplay between High Mobility Group Box 1 (HMGB1) and coagulation: Defining a role for G protein-coupled receptors (GPCRs) in this complex Coag-Inflammatory nexus
BOSAKHAR, Zainab Y H A H A (Post Grad Student) Currie, Susan (Co-investigator) Plevin, Robin (Academic) Cunningham, Margaret Rose (Principal Investigator)
01-Jan-2020 - 30-Jan-2023
Doctoral Training Partnership 2020-2021 University of Strathclyde | Geiser, Angéline
Gould, Gwyn (Principal Investigator) Currie, Susan (Co-investigator) Geiser, Angéline (Research Co-investigator)
01-Jan-2020 - 01-Jan-2024
Investigating connexin 43 expression in adult cardiac fibroblasts
Currie, Susan (Principal Investigator)
31-Jan-2019 - 30-Jan-2019
Investigating the biomolecular complexity of drug-induced cardiotoxicity by fingerprinting single cell and cardiac spheroid mass spectral information using Time-of-flight Secondary Ion Mass Spectrometry (TOF-SIMS)
Cunningham, Margaret Rose (Principal Investigator) Veerman, Ben (Post Grad Student) Johnston, Blair (Co-investigator) Currie, Susan (Co-investigator)
The aim of this project is to significantly advance upon ongoing efforts in understanding drug-induced cardiotoxicity not only at the single cell level but in a multicellular model that may better reflect the cellular microenvironment of the heart. Extending studies to assess the metabolite changes in the multicellular environment in response to cancer therapeutics may reveal events integral to toxicity which may lead to new knowledge to develop ways to minimise or prevent cellular toxicity in the cardiac niche.
01-Jan-2019 - 28-Jan-2022
Investigating the translational application of CaMKII as a biomarker for cobalt cardiotoxicity
Currie, Susan (Principal Investigator) Grant, Mary (Co-investigator) Tate, Rothwelle (Co-investigator)
01-Jan-2019 - 31-Jan-2021

More projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Hamnett Wing

Location Map

View University of Strathclyde in a larger map